What's Inside
- Blind women doing early detection of breast cancer in India.
- Sharks with retinal mutation may hold cure for retinal diseases.
- And, a number of other articles about the science, medicine and prevention of blindness from all over the world.
Editorial By Chris Hofstader
This was a particularly slow week for science stories in the blindness field. This edition contains a number of interesting articles and we hope you enjoy them.
Disclaimer
World Blind herald does not write the stories to which we link in Science Briefs, we gather them, curate them and bring them to our readers. We are not scientists ourselves and cannot guarantee the validity of the stories in this digest. We do, however, want to be very clear that you should not attempt any of the medical interventions mentioned in Science Briefs without first consulting a professional ophthalmologist and discussing it with them. Do not take medical advice from this or any other web site or podcast without first consulting a professional.
Please Subscribe
Advertisement
Blind Girl Designs
Blind Girl Designs, fun and unique apparel for you!
We have creative, delightful, white cane inspired prints on T-shirts, sweatshirts and hoodies.
We also carry dresses and cardigans size Small-XXL.
Call us at 862-448-1011, for an audio description or to place an order. Visit our website.
Science and Medicine
Lumata Health and Prevent Blindness Announce Partnership to Deliver More Resources to Americans with Vision Loss
The partnership addresses a major gap in providing resources for patients with vision impairment or blindness, including a new focus on mental health care delivery. This story comes to us from: Business Wire.
The blind women detecting early stage breast cancer in India
less than 1% of women had undergone breast cancer screening between 2019 and 2021 across India. This story comes to us from: BBC.
Dr. Shroff’s Charity Eye Hospitals partners with Vision Aid India and SHG Technologies to launch smart glasses for visually challenged
The latest version is lightweight and features an improved camera, sensor, and AI/ML technology, making it even more effective in assisting users. This story comes to us from: The Financial Express.
Whale sharks see in dark due to mutation behind blindness in humans
The genetic mutation in the whale shark's eyes activates visual pigments that sense blue light, the only color that reaches the deep sea, based on temperature changes, according to researchers from the National Institute of Genetics, Osaka. This story comes to us from: The Japan Times.
These Eye-Critical Carotenoids Help Prevent AMD Later In Life
The body doesn’t make carotenoids endogenously (i.e., on its own), so you need to consume them via foods containing lutein and zeaxanthin such as (leafy greens, green peas, orange peppers, eggs) and astaxanthin (salmon, lobster, algae, shrimp) or a quality supplement that contains efficacious doses of lutein (10 milligrams), zeaxanthin (2 milligrams), and astaxanthin (6 milligrams). This story comes to us from: MindBodyGreen.
Dr. Shroff's Charity Eye Hospitals partners with Vision Aid India and SHG Technologies
At the launch event, 20 blind and visually impaired individuals were provided the latest Smart Vision Glasses. This story comes to us from: The Financial Express.
Ray Therapeutics to Present at Upcoming Scientific Conferences
Ray Therapeutics, a biotech company developing optogenetic gene therapies for patients with blinding diseases including RP, announced today that Peter Francis, M.D., Ph.D., Chief Scientific and Medical Officer, will present at two upcoming scientific conferences: the 2023 Cell & Gene Meeting on the Med and the Eighth Annual Retinal Cell and Gene Therapy Innovation Summit (held during the 2023 ARVO Annual Meeting). This story comes to us from: Business Wire.
Atsena Therapeutics Announces Six-Month Data from Phase I/II Clinical Trial of ATSN-101 to be Presented at ARVO 2023 Annual Meeting
Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, today announced that 6-month safety and efficacy data from the ongoing Phase I/II clinical trial of ATSN-101 in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D (LCA1) will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting, which is being held April 23-27 in New Orleans, LA.